TIDES Europe 2025
Nucleic Acid Insights 2025; 2(8), 163–164
DOI: 10.18609/nuc.2025.023
As part of our ongoing coverage of major gatherings in the advanced therapeutics space, Nucleic Acid Insights presents a preview of TIDES Europe 2025. Scheduled for November 11–13, 2025, in Basel, Switzerland, this conference will spotlight key strategies, trends, and technologies in oligonucleotide and peptide discovery, development, and manufacturing. In this preview, we highlight key sessions, speakers, and themes that will shape the conversation at one of Europe’s most anticipated nucleic acid events.
Keynote sessions: driving the future of nucleic acid-based drug development
The keynote sessions will spotlight cutting-edge innovations in the nucleic acids field, including oligonucleotide therapeutics for cardiovascular diseases and AI-driven drug discovery. Shalini Andersson (VP of Oligonucleotide Discovery, AstraZeneca) will showcase how antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) can precisely modulate gene expression and protein synthesis to treat heart disease with greater efficacy and fewer side effects. Her talk will emphasize the potential of targeted delivery to expand the druggable space in cardiovascular medicine. Additionally, Brendan Frey (Founder & Chief Innovation Officer, Deep Genomics) will explore how AI foundation models are transforming pharmaceutical R&D by integrating diverse tasks, scaling with data, and improving target accuracy. He will highlight applications in ASOs, siRNAs, mRNAs, and RNA/DNA editing, drawing on Deep Genomics’ internal programs and partnerships to illustrate how these models are accelerating drug development and unlocking new therapeutic possibilities.
Expanding therapeutic impact through novel technologies
The event also includes sessions that will showcase transformative strategies for advancing next-generation oligonucleotide therapeutics through platform innovation, regulatory insight, and molecular engineering. Chris Hart (VP, Data Science and AI/ML, Eli Lilly and Company) will highlight how oligonucleotide medicines are evolving into best-in-class treatments for both rare and prevalent diseases, emphasizing collaborative efforts in delivery technologies and molecular engineering to expand therapeutic impact. Jennifer Franklin (Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals) will share practical insights into applying platform data for oligonucleotide development, including regulatory engagement and future directions for health authority interactions. Lastly, Firoz Antia (VP, Oligonucleotide & Small Molecule CMC, Denali Therapeutics) will present key CMC considerations for Denali’s Oligonucleotide Transport Vehicle (OTV) platform and antibody-ASO conjugates, offering a deep dive into how these innovations are shaping delivery and manufacturing strategies. Together, these sessions will provide a comprehensive view of how oligonucleotide platforms are driving therapeutic breakthroughs and regulatory evolution.
TIDES Europe 2025 is one of Europe’s leading events for nucleic acid therapeutics, bringing together over 750 attendees and over 100 speakers. Held in Basel, the event will feature cutting-edge presentations on therapeutic innovation, scalable manufacturing, and advanced nucleic acid delivery technologies. With a focus on expanding therapeutic impact and overcoming development bottlenecks, TIDES Europe offers a comprehensive view into the future of nucleic acid-based medicines and next-generation biologics.
As a reader of Nucleic Acid Insights, you’re entitled to a 10% discount on delegate tickets—just use this link! You can find out more about the TIDES Europe 2025 events here.
Want to keep up to date with all of the latest nucleic acid events you might want to attend or exhibit at? Explore our free online Events Calendar here.